Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Misses on EPS, Stock Up 5.0%

Corvus Pharmaceuticals reported a loss that was larger than expected, which typically raises concerns among investors. However, the stock rose by 5% following the earnings report, indicating that investors may have reacted positively to other aspects of the company's performance or future potential. The lack of revenue and guidance makes it challenging to assess the company's trajectory moving forward.